Soliris Europese Unie - Deens - EMA (European Medicines Agency)

soliris

alexion europe sas - eculizumab - hemoglobinuri, paroxysmal - immunosuppressiva - soliris er indiceret hos voksne og børn til behandling af:paroksysmal natlig haemoglobinuria (pnh). dokumentation af klinisk fordel er påvist hos patienter med haemolysis med klinisk symptom(er) betegnende for høj sygdomsaktivitet, uanset transfusion historie (se afsnit 5. atypiske hæmolytisk uræmisk syndrom (ahus). soliris er indiceret hos voksne til behandling af:ildfaste generaliseret myasthenia gravis (gmg) i patienter, der er anti-acetylcholin-receptor (achr) antistof-positive (se afsnit 5. neuromyelitis optica spektrum forstyrrelse (nmosd) i patienter, der er anti-aquaporin-4 (aqp4) antistof-positive med en recidiverende forløbet af sygdommen.

Atacand 16 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand 16 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 16 mg

Atacand 32 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand 32 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 32 mg

Atacand 8 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand 8 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 8 mg

Atacand Zid 16 mg/12,5 mg 16+12,5 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand zid 16 mg/12,5 mg 16+12,5 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil, hydrochlorthiazid - tabletter - 16+12,5 mg

Atacand Zid 32 mg/12,5 mg 32+12,5 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand zid 32 mg/12,5 mg 32+12,5 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil, hydrochlorthiazid - tabletter - 32+12,5 mg

Atacand Zid 32mg /25 mg 32+25 mg tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atacand zid 32mg /25 mg 32+25 mg tabletter

cheplapharm arzneimittel gmbh - candesartancilexetil, hydrochlorthiazid - tabletter - 32+25 mg

Imfinzi Europese Unie - Deens - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Symbicort 2,25+80 mikrog/dosis inhalationsspray, suspension Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

symbicort 2,25+80 mikrog/dosis inhalationsspray, suspension

astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 2,25+80 mikrog/dosis

Crestor 10 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

crestor 10 mg filmovertrukne tabletter

abacus medicine a/s - rosuvastatin calcium - filmovertrukne tabletter - 10 mg